APT Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From APT Pharmaceuticals, Inc.
Accelerated initial public listings, multi-million dollar deals and hot investment fund influxes fuel an already record-setting July for biotech fundraising in China.
Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.
Hot on the heels of a high-profile US approval, Chinese biotechs from BeiGene, Betta to Zai Lab and lesser-known InventisBio, are racing to get their KRAS-targeting cancer drugs launched. Zai Lab, however, hopes to win with a potential best-in-class contender from its partner Mirati of the US.
Dermatologists have compared the current market for vitiligo to that of psoriasis 30 years ago, which grew from one with a dearth of therapies to one worth about $8bn.